THERAtRAME builds first-in-class tRNA drugs for the patients today’s cancer therapies can’t reach.
THERAtRAME is a clinical-stage biotechnology company developing first-in-class oncology therapies by inhibiting tRNA-modifying enzymes, a largely untapped yet highly transformative space in cancer biology.
Founded in 2022 as a spin-off from the University of Liège and the WEL Research Institute. THERAtRAME focuses on immune-refractory and highly resistant tumors, addressing the large population of patients who do not benefit from current targeted therapies or immunotherapy.
Powered by EpiFind, our proprietary tRNA-centric platform identifies and validates translational vulnerabilities that drive cancer plasticity, resistance, and immune evasion.
Our lead asset, a first-in-class small-molecule tRNA-enzyme inhibitor, combines synthetic lethality with CD4-mediated immune modulation, delivering both direct tumor cell killing and tumor-specific immune activation. Supported by strong in vivo efficacy, oral bioavailability, and a clear clinical roadmap, we are advancing toward first-in-human trials.
THERAtRAME’s ambition is simple: unlock new therapeutic options where current standards of care fail.
More about us
What drives us is the opportunity to turn our discoveries in tRNA epitranscriptomics into real clinical solutions, offering new hope to patients with cancer.”
What we do...
Key point 1
Consectetur adipisicing elit. Voluptas quidem numquam atque totam veniam sed delectus consequatur accusamus assumenda illo volmi vel exercitatisoluta nonid recusandae incidunt dolorestiae, sunt harum. Explicabo perferendis hic quas aliquam, eaque saepe, tempore aperiam error, vero vel, minus! Repudiandae id vel aut doloribus minima modi quia, maiores veniam. Quidem?
Key point 2
Lorem, ipsum dolor sit amet consectetur adipisicing elit. Voluptas quidem numquam atque totam veniam sed delectus consequatur accusamus assumenda illo volmi vel exercitatisoluta nonid recusandae incidunt dolores asperiores quam optio molestiae, sunt harum. Explicabo perferendis hic quas aliquam, eaque saepe, tempore aperiam error, vero vel, minus! Repudiandae id vel aut doloribus minima modi quia, maiores veniam. Quidem?
Key point 3
Ipsum dolor sit amet consectetur adipisicing elit. Voluptas quidem numquam atque totam veniam sed delectus cona illo volmi vel exercitatisoluta nonid recusandae incidunt dolores asperiores quam optio molestiae, sunt harum. Explicabo perferendis hic quas e aperiam error, vero vel, minus! Repudiandae id vel aut doloribus minima modi quia, maiores veniam. Quidem?
